最新研究进展 -MedSci.cn 相关研究进展 -MedSci.cn

筛选条件 共查询到500条结果

排序方式

文献标题

第一作者

所属期刊

影响指数

重置筛选

The role of primary tumor resection in synchronous stage IV colorectal cancer: Subgroup analysis.

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ()

Prostate cancer screening: Have we tipped the seesaw?

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ()

Prognostic stratification by the Meet-URO score in a real-world elderly population of patients (pts) with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: A subanalysis of the prospective ZEBRA study (Meet-URO 9).

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ()

Gene signatures for predicting the response to immune checkpoint inhibitor by integrating bulk and single-cell sequence data in patients with bladder cancer.

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ()

Combined alternating sunitinib and bevacizumab in the management of advanced renal cell carcinoma: A phase I/II trial.

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 ()

Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (7)

PURPOSETo determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care.METHODSParti......

Redefining Gleason 6 Prostate Cancer Nomenclature: The Surgeon's Perspective

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (7)

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

Effect of GNA13 on the alteration of tumor microenvironmental components through exosomes to promote the development of head and neck tumors

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

A phase Ib study of porustobart (HBM4003), an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in patients with hepatocellular carcinoma

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: Incidence, pattern of failure and clinical value of local consolidative therapy

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

Homologous recombination deficiency (HRD) status and response to platinum-based chemotherapy and PARP inhibitors in Chinese patients with ovarian cancer.

期刊： JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16)

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

科室

工具

服务